A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer

This trial is testing a new oral drug called HRS-5041 in men with metastatic castration-resistant prostate cancer — meaning prostate cancer that has spread to other parts of the body and no longer responds to hormone therapy. The study is evaluating the drug's safety, how the body processes it, and whether it helps fight the cancer. **You may be eligible if...** - You have been diagnosed with metastatic castration-resistant prostate cancer - Your blood counts, kidney, and liver function are adequate - You are willing and able to understand the study and its possible side effects **You may NOT be eligible if...** - You plan to receive any other anti-cancer treatment during the study - You have received chemotherapy, radiation, immunotherapy, or surgery within 4 weeks of starting the study - You have uncontrolled high blood pressure - You have difficulty swallowing or chronic digestive problems that could affect how the drug is absorbed Talk to your doctor to see if this trial is right for you.